Your browser doesn't support javascript.
loading
Calcium and Magnesium Use for Oxaliplatin-Induced Neuropathy: A Case Study to Assess How Quickly Evidence Translates Into Practice.
Pachman, Deirdre R; Ruddy, Kathryn; Sangaralingham, Lindsey R; Grothey, Axel; Shah, Nilay D; Beutler, Andreas S; Hubbard, Joleen M; Loprinzi, Charles L.
Afiliação
  • Pachman DR; From the Department of Oncology, Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, and Health Care Policy & Research, Mayo Clinic, Rochester, Minnesota; and Optum Labs, Cambridge, Massachusetts.
  • Ruddy K; From the Department of Oncology, Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, and Health Care Policy & Research, Mayo Clinic, Rochester, Minnesota; and Optum Labs, Cambridge, Massachusetts.
  • Sangaralingham LR; From the Department of Oncology, Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, and Health Care Policy & Research, Mayo Clinic, Rochester, Minnesota; and Optum Labs, Cambridge, Massachusetts.
  • Grothey A; From the Department of Oncology, Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, and Health Care Policy & Research, Mayo Clinic, Rochester, Minnesota; and Optum Labs, Cambridge, Massachusetts.
  • Shah ND; From the Department of Oncology, Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, and Health Care Policy & Research, Mayo Clinic, Rochester, Minnesota; and Optum Labs, Cambridge, Massachusetts. From the Department of Oncology, Robert D. and Patricia E. Kern Center f
  • Beutler AS; From the Department of Oncology, Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, and Health Care Policy & Research, Mayo Clinic, Rochester, Minnesota; and Optum Labs, Cambridge, Massachusetts.
  • Hubbard JM; From the Department of Oncology, Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, and Health Care Policy & Research, Mayo Clinic, Rochester, Minnesota; and Optum Labs, Cambridge, Massachusetts.
  • Loprinzi CL; From the Department of Oncology, Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, and Health Care Policy & Research, Mayo Clinic, Rochester, Minnesota; and Optum Labs, Cambridge, Massachusetts.
J Natl Compr Canc Netw ; 13(9): 1097-101, 2015 Sep.
Article em En | MEDLINE | ID: mdl-26358793
ABSTRACT
Substantial research efforts have focused on methods of treating and preventing oxaliplatin-associated neuropathy, the dose-limiting toxicity associated with this drug. Administration of intravenous calcium and magnesium (CaMg) before and after oxaliplatin has been the most studied approach to preventing oxaliplatin-induced neuropathy. Although early reports demonstrated potential benefit, subsequent larger trials failed to confirm the efficacy of CaMg in preventing this adverse effect. This article explores how accumulating evidence for and against the use of CaMg for preventing oxaliplatin-induced neuropathy has impacted clinical practice.
Assuntos
Buscar no Google
Imprimir
XML
PubMed Links

Eixos temáticos: Pesquisa_clinica Base de dados: MEDLINE Assunto principal: Compostos Organoplatínicos / Padrões de Prática Médica / Cálcio / Doenças do Sistema Nervoso Periférico / Magnésio / Antineoplásicos Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans País como assunto: America do norte Idioma: En Ano de publicação: 2015 Tipo de documento: Article
Buscar no Google
Imprimir
XML
PubMed Links

Eixos temáticos: Pesquisa_clinica Base de dados: MEDLINE Assunto principal: Compostos Organoplatínicos / Padrões de Prática Médica / Cálcio / Doenças do Sistema Nervoso Periférico / Magnésio / Antineoplásicos Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans País como assunto: America do norte Idioma: En Ano de publicação: 2015 Tipo de documento: Article